… treated with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
erlotinib, which improves patient outcomes in second-line therapy 9 and in first-line treatment for …

… Among treatment modalities for lung cancer, the most promising therapy is the use of epidermal
growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). Both erlotinib and gefitinib, …

… The presence of an epidermal growth factor receptor (EGFR) mutation identifies a subset of
… In conclusion, we have observed that reduced-dose erlotinib for the treatment of patients with …

… erlotinib is a promising treatment for … growth factor (VEGF). A previous preclinical study
demonstrated that plasma VEGF and tumor VEGF mRNA levels increased after erlotinib treatment …

… treatment options. Although targeted therapy, using tyrosine-kinase inhibitors such as erlotinib
… , only 15 % patients with mutated epidermal growth factor receptor (EGFR) in lung cancer …

… not display amplification of the human epidermal growth factor receptor 2 (HER2) gene. …
treatment for TNBC. In 2019, atezolizumab, a PD-L1 inhibitor, was approved for the treatment of …

… [ 21 ] Erlotinib is a FDA-approved therapy for the treatment of … Erlotinib prevention of oral
cancer study is the largest EGFR-… was to determine whether erlotinib can reduce oral cancer …

… treatment with the epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI),
erlotinib. … impair the patient’s compliance with the treatment or even cause its discontinuation. In …

… of erlotinib treatment in patients expressing wild-type epidermal growth factor receptor (…
(NS‑NSCLC) and wild‑type EGFR who were treated with erlotinib alone as second- or later‑line …

… Results: 449 pts were randomized characteristics were balanced between treatment arms:
Asian 77%, Females 63%, Ex19del 54%. RAM + ERL significantly prolonged PFS, DoR, and …